Materias dentro de su búsqueda.
Mostrando 926,341 - 926,360 Resultados de 928,171 Para Buscar '"8½"', tiempo de consulta: 5.02s Limitar resultados
  1. 926341
    por Seyed Khoei, Nazlisadat, Jenab, Mazda, Murphy, Neil, Banbury, Barbara L., Carreras-Torres, Robert, Viallon, Vivian, Kühn, Tilman, Bueno-de-Mesquita, Bas, Aleksandrova, Krasimira, Cross, Amanda J., Weiderpass, Elisabete, Stepien, Magdalena, Bulmer, Andrew, Tjønneland, Anne, Boutron-Ruault, Marie-Christine, Severi, Gianluca, Carbonnel, Franck, Katzke, Verena, Boeing, Heiner, Bergmann, Manuela M., Trichopoulou, Antonia, Karakatsani, Anna, Martimianaki, Georgia, Palli, Domenico, Tagliabue, Giovanna, Panico, Salvatore, Tumino, Rosario, Sacerdote, Carlotta, Skeie, Guri, Merino, Susana, Bonet, Catalina, Rodríguez-Barranco, Miguel, Gil, Leire, Chirlaque, Maria-Dolores, Ardanaz, Eva, Myte, Robin, Hultdin, Johan, Perez-Cornago, Aurora, Aune, Dagfinn, Tsilidis, Konstantinos K., Albanes, Demetrius, Baron, John A., Berndt, Sonja I., Bézieau, Stéphane, Brenner, Hermann, Campbell, Peter T., Casey, Graham, Chan, Andrew T., Chang-Claude, Jenny, Chanock, Stephen J., Cotterchio, Michelle, Gallinger, Steven, Gruber, Stephen B., Haile, Robert W., Hampe, Jochen, Hoffmeister, Michael, Hopper, John L., Hsu, Li, Huyghe, Jeroen R., Jenkins, Mark A., Joshi, Amit D., Kampman, Ellen, Larsson, Susanna C., Le Marchand, Loic, Li, Christopher I., Li, Li, Lindblom, Annika, Lindor, Noralane M., Martín, Vicente, Moreno, Victor, Newcomb, Polly A., Offit, Kenneth, Ogino, Shuji, Parfrey, Patrick S., Pharoah, Paul D. P., Rennert, Gad, Sakoda, Lori C., Schafmayer, Clemens, Schmit, Stephanie L., Schoen, Robert E., Slattery, Martha L., Thibodeau, Stephen N., Ulrich, Cornelia M., van Duijnhoven, Franzel J. B., Weigl, Korbinian, Weinstein, Stephanie J., White, Emily, Wolk, Alicja, Woods, Michael O., Wu, Anna H., Zhang, Xuehong, Ferrari, Pietro, Anton, Gabriele, Peters, Annette, Peters, Ulrike, Gunter, Marc J., Wagner, Karl-Heinz, Freisling, Heinz
    Publicado 2020
    “…Additionally, 115 single-nucleotide polymorphisms (SNPs) robustly associated (P < 5 × 10(−8)) with circulating total bilirubin were instrumented in a 2-sample MR to test for a potential causal effect of bilirubin on CRC risk in 52,775 CRC cases and 45,940 matched controls in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), the Colon Cancer Family Registry (CCFR), and the Colorectal Transdisciplinary (CORECT) study. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Circulating bilirubin levels and risk of colorectal cancer: serological and Mendelian randomization analyses
  2. 926342
    “…Corticosteroid-treated participants showed stunting of growth, whereas vamorolone-treated trial participants did not (p < 0.001; LS mean 15.86 [95% CI 8.51, 23.22]). Physician-reported incidences of adverse events (AEs) for Cushingoid appearance, hirsutism, weight gain, and behavior change were less for vamorolone than published incidences for prednisone and deflazacort. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study
  3. 926343
    “…Compared with patients who tested negative for SARS-CoV-2, those who tested positive had higher rates of 30-day hospitalization (30.4% vs 29.3%; adjusted hazard ratio [aHR], 1.13; 95% CI, 1.08-1.13), mechanical ventilation (6.7% vs 1.7%; aHR, 4.15; 95% CI, 3.74-4.61), and death (10.8% vs 2.4%; aHR, 4.44; 95% CI, 4.07-4.83). Among patients who tested positive for SARS-CoV-2, characteristics significantly associated with mortality included older age (eg, ≥80 years vs <50 years: aHR, 60.80; 95% CI, 29.67-124.61), high regional COVID-19 disease burden (eg, ≥700 vs <130 deaths per 1 million residents: aHR, 1.21; 95% CI, 1.02-1.45), higher Charlson comorbidity index score (eg, ≥5 vs 0: aHR, 1.93; 95% CI, 1.54-2.42), fever (aHR, 1.51; 95% CI, 1.32-1.72), dyspnea (aHR, 1.78; 95% CI, 1.53-2.07), and abnormalities in the certain blood tests, which exhibited dose-response associations with mortality, including aspartate aminotransferase (>89 U/L vs ≤25 U/L: aHR, 1.86; 95% CI, 1.35-2.57), creatinine (>3.80 mg/dL vs 0.98 mg/dL: aHR, 3.79; 95% CI, 2.62-5.48), and neutrophil to lymphocyte ratio (>12.70 vs ≤2.71: aHR, 2.88; 95% CI, 2.12-3.91). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 Infection
  4. 926344
    “…For patients with convulsive refractory status epilepticus (CRSE), we sought to determine the strength of evidence for 8 parenteral ASMs used as third-line treatment in stopping clinical CRSE. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee
  5. 926345
    “…An increasing trend over time in the R ratio was found following the relaxation of school closure, bans on public events, bans on public gatherings of more than ten people, requirements to stay at home, and internal movement limits; the increase in R ranged from 11% to 25% on day 28 following the relaxation compared with the last day before relaxation, although the increase was significant only for school reopening (R ratio 1·24, 95% CI 1·00–1·52) and lifting bans on public gatherings of more than ten people (1·25, 1·03–1·51); for all other NPIs, the lower bound of the 95% CI was below 1. It took a median of 8 days (IQR 6–9) following the introduction of an NPI to observe 60% of the maximum reduction in R and even longer (17 days [14–20]) following relaxation to observe 60% of the maximum increase in R. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries
  6. 926346
    por Hässler, Signe, Bachelet, Delphine, Duhaze, Julianne, Szely, Natacha, Gleizes, Aude, Hacein-Bey Abina, Salima, Aktas, Orhan, Auer, Michael, Avouac, Jerôme, Birchler, Mary, Bouhnik, Yoram, Brocq, Olivier, Buck-Martin, Dorothea, Cadiot, Guillaume, Carbonnel, Franck, Chowers, Yehuda, Comabella, Manuel, Derfuss, Tobias, De Vries, Niek, Donnellan, Naoimh, Doukani, Abiba, Guger, Michael, Hartung, Hans-Peter, Kubala Havrdova, Eva, Hemmer, Bernhard, Huizinga, Tom, Ingenhoven, Kathleen, Hyldgaard-Jensen, Poul Erik, Jury, Elizabeth C., Khalil, Michael, Kieseier, Bernd, Laurén, Anna, Lindberg, Raija, Loercher, Amy, Maggi, Enrico, Manson, Jessica, Mauri, Claudia, Mohand Oumoussa, Badreddine, Montalban, Xavier, Nachury, Maria, Nytrova, Petra, Richez, Christophe, Ryner, Malin, Sellebjerg, Finn, Sievers, Claudia, Sikkema, Dan, Soubrier, Martin, Tourdot, Sophie, Trang, Caroline, Vultaggio, Alessandra, Warnke, Clemens, Spindeldreher, Sebastian, Dönnes, Pierre, Hickling, Timothy P., Hincelin Mery, Agnès, Allez, Matthieu, Deisenhammer, Florian, Fogdell-Hahn, Anna, Mariette, Xavier, Pallardy, Marc, Broët, Philippe
    Publicado 2020
    “…METHODS AND FINDINGS: The European consortium ABIRISK (Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK) conducted a clinical and genomic multicohort prospective study of 560 patients with multiple sclerosis (MS, n = 147), rheumatoid arthritis (RA, n = 229), Crohn’s disease (n = 148), or ulcerative colitis (n = 36) treated with 8 different biopharmaceuticals (etanercept, n = 84; infliximab, n = 101; adalimumab, n = 153; interferon [IFN]-beta-1a intramuscularly [IM], n = 38; IFN-beta-1a subcutaneously [SC], n = 68; IFN-beta-1b SC, n = 41; rituximab, n = 31; tocilizumab, n = 44) and followed during the first 12 months of therapy for time to ADA development. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium
  7. 926347
    “…La biologie objective une insuffisance rénale aigue avec urée à 10,1 mmol/L, créatinine à 172 micromol/L (DFG-CKD-EPI 39 mL/min/m(2)), un syndrome inflammatoire avec une CRP à 223 mg/L et une polynucléose neutrophiles (11,8 G/L) et une cholestase à 2 fois la normale. Le pic de troponine HS est à 919 ng/L (norme < 78,5). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Tamponnade & COVID-19
  8. 926348
    “…Mean scores for PANSS total at the 6-month primary endpoint were 68·6 (SD 17·3) for antipsychotic monotherapy (6·2 points lower than at randomisation), 59·8 (13·7) for psychological intervention (13·1 points lower than at randomisation), and 62·0 (15·9) for antipsychotics plus psychological intervention (13·9 points lower than at randomisation). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study
  9. 926349
    “…She had been afebrile after the acute COVID-19 infection and her persistent positive results were explained as related viral shedding over a period of 8 weeks. One week later, she represented to hospital with fever, cough and shortness of breath, and her blood results showed a remarkable rise in inflammatory markers, including a CRP of 242. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    O02 Persistent non-fulminant COVID-19 infection in a GPA patient on rituximab
  10. 926350
    “…Physical examination revealed 5x 8 cm swelling on Right buttock, Rest of examination was unremarkable. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    O21 A rare case of anti-TNF induced panniculitis
  11. 926351
    “…Healthy children and adolescents aged 1–17 years were enrolled in three age cohorts (12–17 years, 4–11 years, and 1–3 years) and randomly assigned (3:1), via computer-generated block randomisation (block size of eight), to receive an intramuscular injection of either Ad26.ZEBOV (5 × 10(10) viral particles; first dose) followed by MVA-BN-Filo (1 × 10(8) infectious units; second dose) on day 57 (Ebola vaccine group), or a single dose of meningococcal quadrivalent (serogroups A, C, W135, and Y) conjugate vaccine (MenACWY; first dose) followed by placebo (second dose) on day 57 (control group). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
  12. 926352
    “…In addition, people with lower education showed a higher index of depression and anxiety than people with higher education (cut-off point for higher education was a bachelor's degree; SDS 14·06, 12·63–15·68, vs SDS 35·03, 30·89–39·09, p=0·0010; SAS 8·52, 6·81–10·34, vs SAS 25·75, 22·41–29·13, p=0·0010). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The attitude and psychological status of medical staff in China during the COVID-19 outbreak: a cross-sectional survey
  13. 926353
    “…From Jan 23, 2020 to Feb 27, 2020, 69 rheumatologists from 28 hospitals provided 1451 patients with 1692 consultations and supplied 566 (39%) of them with continued medication, which included 55 commonly used therapeutic drugs for rheumatic diseases. 247 (8%) of 3237 patients with rheumatoid arthritis during the 2020 epidemic and 350 (9%) in same period during 2018 and 2019 did the DAS28 self-assessments, and T2T was 47% in 2020 compared with 50% in 2018 and 2019, (p=0·53). 293 (19%) of 1566 patients with systemic lupus erythematosus in 2020 and 210 (16%) in 2018 and 2019 did the SLESAI-2K self-assessments, and LLDAS was 60% in 2020 compared with 47% in 2018 and 2019 (p=0·03). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Smart system of disease management for patient follow-up and medication refill during the COVID-19 epidemic period: a multicentre retrospective cohort study
  14. 926354
    “…RÉSULTATS: Un total de 1418 patients étaient inclus dont les caractéristiques sont précisées dans le tableau. 22,4 % des patients sous traitement systémique et 13,8 % de ceux sous biologique ont arrêté leur traitement au cours de l’épidémie. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Pas de sur-risque de forme grave de COVID-19 chez les patients sous traitement systémique ou biologique pour du psoriasis
  15. 926355
    “…La médiane de réalisation de la sérologie était de 28 jours (IQR 26,5–31) dans le groupe confirmé vs 22,5 jours (IQR 8,5–33,3). Une photographie était disponible chez 56 patients dont 38 dans le groupe COVID. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Manifestations cutanées au cours l’épidémie de COVID-19 : étude COVID-Skin de la Société française de dermatologie
  16. 926356
    “…RÉSULTATS: Un total de 7 808 patients (âge médian 45 ans, 51 % de femmes) étaient inclus, dont 48 avec un diagnostic d’infection à SARS-CoV-2, 19 (40 %) hospitalisés, 4 (8 %) en ICU et 1 décès. En comparaison avec la population d’Ile-de-France, les taux d’hospitalisation et d’ICU étaient significativement élevés chez les patients sous BM avec SR = 2,19, 95 %CI 1,32–3,42, p < 0,001 et SR = 6,04, 95 %CI 1,62–15,45, p < 0,001 respectivement, significativement observés chez les [20–40]. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Infection à SARS-CoV-2 et biomédicaments : étude multicentrique française de 7808 patients
  17. 926357
    “…RÉSULTATS: Un total de7808 patients (âge médian 45 ans, 51 % de femmes) étaient inclus ; dont 48 avec un diagnostic d’infection à COVID-19 : 19 (40 %) hospitalisés, 4 (8 %) en ICU et 1 décès. En comparaison avec la population d’Ile-de-France, les taux d’hospitalisation et d’ICU étaient significativement élevés chez les patients sous BM avec SMR 2,19, IC95 % 1,32-3,42, p < 0,001 et SMR 6,04, IC95 % 1,62-15,45, p < 0,001 respectivement, significativement observés chez les [20-40[. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Infection à SARS-CoV-2 et biomédicaments : une étude multicentrique française de 7808 patients
  18. 926358
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and Efficacy of Ixekizumab and Antiviral Treatment for Patients with COVID-19: A structured summary of a study protocol for a Pilot Randomized Controlled Trial
  19. 926359
    “…S rates as per US FDA and USCAST criteria were 97.4% and 90.2% for AMK, 86.4% and 85.6% for GEN, and 83.8% and 81.1% for TOB, respectively (Table). CLSI and US FDA breakpoints were identical for these three older aminoglycosides, and EUCAST breakpoints were identical for GEN and TOB and one doubling dilution higher for AMK when compared with USCAST. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1278. Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales resistant Subsets to the Aminoglycosides
  20. 926360
    “…Clindamycin (CLI; >99.0%S) and levofloxacin (> 95.0%S) were active against methicillin-susceptible SA, but less active against MRSA (67.8%S and 16.1%S, respectively). E-EU MRSA isolates displayed lower S rates than W-EU MRSA isolates to ceftaroline (83.3% vs. 90.6%), CLI (44.4% vs. 74.7%) and tetracycline (66.7% vs. 89.0%), respectively. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    327. Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infections in European Hospitals (2010–2019)
Herramientas de búsqueda: RSS